Uta Oelschlägel

Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial

Uwe Platzbecker, Jan Moritz Middeke, Katja Sockel et al. · The Lancet Oncology · 2018 · 354 citations

Medicine, Hematology, Pharmacology +17

Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia

Armin Ehninger, Michael Krämer, Christoph Röllig et al. · Blood Cancer Journal · 2014 · 352 citations · Full text

Medicine, Hematology, Oncology +16

P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate

Thomas Illmer, Markus Schaich, Uwe Platzbecker et al. · Leukemia · 2004 · 306 citations

Medicine, Pharmacokinetics, Pharmacology +13

Sequential monitoring of chimerism and detection of minimal residual disease after allogeneic blood stem cell transplantation (BSCT) using multiplex PCR amplification of short tandem repeat-markers

Christian Thiede, Martin Bornhäuser, Uta Oelschlägel et al. · Leukemia · 2001 · 220 citations

Medicine, Hematology, Immunology +17

Adoptive transfer of allogeneic regulatory T cells into patients with chronic graft-versus-host disease

Anke Theil, Sebastian Tuve, Uta Oelschlägel et al. · Cytotherapy · 2015 · 178 citations

Life Sciences, Immunology, Clinical Immunology +15